(5-ethylpyridin-2-yl)ethanol | 856954-09-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (5-ethylpyridin-2-yl)ethanol
• 英文别名: (5-Ethyl-2-pyridyl)ethanol；1-(5-ethylpyridin-2-yl)ethanol
• CAS: 856954-09-1
• 化学式: C₉H₁₃NO
• mdl: MFCD08458434
• 分子量: 151.208
• InChiKey: PIPCMPONTDMDST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (5-ethylpyridin-2-yl)ethanol 生成 N-((2-(5-ethylpyridin-2-yl)ethyloxy)carbonyl)-L-leucine ethyl ester
  参考文献：
  名称：

  LISSENCEPHALY THERAPEUTIC AGENT

  摘要：

  公开号：

  EP2647386B1

文献信息

• [EN] ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF<br/>[FR] DERIVE D'ALPHA-CETOAMIDE, SON PROCEDE DE PRODUCTION ET D'UTILISATION
  申请人：SENJU PHARMA CO

  公开号：WO2005056519A1

  公开（公告）日：2005-06-23

  The present invention provides a compound represented by the formula (I): (INSERT CHEMICAL FORMULA) (wherein R1 is a lower alkyl substituted by a lower alkoxy or a heterocyclic group, or a heterocyclic group; R2 is a lower alkyl optionally substituted by a phenyl; and R3 is a lower alkyl optionally substituted by a halogen, a lower alkoxy or a phenyl, or a fused polycyclic hydrocarbon group), which is well absorbed orally, exhibits durability of good blood level and has potent calpain inhibitory activity.

  本发明提供了一种化合物，其化学式表示为（I）：（插入化学式）（其中R1是由低烷基取代的低烷氧基或杂环基，或者是杂环基；R2是可选择地由苯基取代的低烷基；R3是可选择地由卤素、低烷氧基或苯基取代的低烷基，或者是融合的多环碳氢基），该化合物在口服后被很好地吸收，表现出良好的血液水平持久性，并具有强大的钙蛋白酶抑制活性。
• COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER
  申请人：OSAKA CITY UNIVERSITY

  公开号：US20190314320A1

  公开（公告）日：2019-10-17

  The present invention provides a means for treating and/or preventing peripheral nerve disorder by facilitating regeneration of peripheral nerves. Specifically, the present invention provides a composition for treating and/or preventing peripheral nerve disorder comprising a compound represented by the general formula (I): wherein R 1 is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa): R 4 O—R 5  m (IIa) wherein R 4 is lower alkyl, R 5 is lower alkylene, and m is an integer of 1 to 6; R 2 is lower alkyl optionally substituted with phenyl; and R 3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.

  本发明提供了一种治疗和/或预防外周神经障碍的方法，通过促进外周神经再生。具体地，本发明提供了一种用于治疗和/或预防外周神经障碍的组合物，包括由通式（I）表示的化合物： 其中R1为与低烷氧基取代的低烷基，与杂环基取代的低烷基，杂环基，或由式（IIa）表示的基团： R4O—R5m（IIa） 其中R4为低烷基，R5为低烷基烯，m为1至6的整数； R2为可选择地取代苯基的低烷基；和 R3为可选择地取代卤素，低烷氧基，或苯基的低烷基；缩合多环碳氢化合物；或氢。
• [EN] PROCESS FOR PREPARING THIAZOLIDINEDIONES<br/>[FR] PROCEDE DE PREPARATION DE THIAZOLIDINEDIONES
  申请人：SANDOZ AG

  公开号：WO2005049610A1

  公开（公告）日：2005-06-02

  This invention provides a process for reducing an exocyclic double bond at the 5-position of a thiazolidinedione moiety of a thiazolidinedione precursor comprising the steps of: a) preparing a solution or suspension of the thiazolidinedione precursor in a non-ether solvent medium with a base, and b) combining the solution or suspension with a dithionite source. Preferred solvent media include aqueous N,N-dimethylformamide. Sodium dithionite is a preferred dithionite source. In particular the application discloses preparation processes for Pioglitazone, Rosilitazone and Troglitazone.

  这项发明提供了一种在噻唑烷二酮前体的噻唑烷二酮部分的5位外环双键还原的方法，包括以下步骤：a)在非醚溶剂介质中与碱制备噻唑烷二酮前体的溶液或悬浮液，b)将溶液或悬浮液与二亚硫酸盐源结合。首选溶剂介质包括水合二甲基甲酰胺。硫代硫酸钠是一种首选的二亚硫酸盐源。特别是该申请揭示了派格列酮、罗格列酮和曲格列酮的制备过程。
• Ether and amide compounds and preparation of thereof as antidiadetics.
  申请人：——

  公开号：US20010008898A1

  公开（公告）日：2001-07-19

  Ether and amide derivatives are disclosed, which are represented by the following formula (I) and its pharmaceutical acceptable salt, and which are useful for the treatment of diabetes. 1 (with the provisos that (i) when A is —O—, then n is 2 or 3 (ii) when A is 2 then n is 1 or 2. R 3 is OH—, CH 3 SO 2 NH—, CF 3 SO 2 NH—, CH 3 SO 2 NHCH 2 —, CF 3 SO 2 NHCH 2 —, HOOC—, CH 3 OOC—, 3 HOOC—CH 2 SO 2 NH—, CF 3 —CH 2 SO 2 NH—, 4 R 8 —NHSO 2 —, R 8 —NHSO 2 —CH 2 —, HOOC—CH 2 —O—, HSO 3 N═CH—, or R 9 —SO 2 NHCO—; R 4 is H, OH, O-alkyl or O—CH 2 OCH 3 ; R 5 is H, halogen atom, —CH 2 COOH or OH; R 6 and R 7 are hydrogen, t-butyl or pyrolidyl; R 8 is hydrogen or lower alkyl; R 9 is alkyl or thienyl; R 10 is lower alkyl) or a pharmaceutically acceptable salt.

  乙醚和酰胺衍生物被披露，其由以下式(I)及其药用可接受盐所代表，并且对于糖尿病的治疗是有用的。 1 （在以下情况下，附加条件为：(i) 当A为—O—时，n为2或3 (ii) 当A为 2 时，n为1或2。R 3 为OH—，CH 3 SO 2 NH—，CF 3 SO 2 NH—，CH 3 SO 2 NHCH 2 —，CF 3 SO 2 NHCH 2 —，HOOC—，CH 3 OOC—， 3 HOOC—CH 2 SO 2 NH—，CF 3 —CH 2 SO 2 NH—， 4 R 8 —NHSO 2 —，R 8 —NHSO 2 —CH 2 —，HOOC—CH 2 —O—，HSO 3 N═CH—，或R 9 —SO 2 NHCO—； R 4 为H，OH，O-烷基或O—CH 2 OCH 3 ； R 5 为H，卤原子，—CH 2 COOH或OH； R 6 和R 7 为氢，叔丁基或吡咯烷基； R 8 为氢或较低烷基； R 9 为烷基或噻吩基； R 10 为较低烷基） 或药用可接受盐。
• [EN] COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS<br/>[FR] COMPOSITIONS ET UTILISATIONS THÉRAPEUTIQUES D'INHIBITEURS DE LA KINASE EPSILON LIÉE À IKK ET DE LA KINASE 1 DE LIAISON À TANK
  申请人：MYREXIS INC

  公开号：WO2012142329A1

  公开（公告）日：2012-10-18

  The invention relates to compounds, pharmaceutical compositions and medicaments comprising such compounds, and the use of these compounds, compositions, and medicaments in methods of treating diseases and disorders.

  这项发明涉及化合物、药物组合物和包含这些化合物的药物，以及在治疗疾病和疾病障碍的方法中使用这些化合物、组合物和药物。